{
  "abstract": "Background/Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with a defined, first-line (1L) standard of care (SOC). Several novel agents have been approved for the treatment of relapsed/refractory (R/R) disease in recent years, leading to a heterogeneous treatment landscape in later lines of therapy (LOTs). Our study aimed to characterize real-world treatment patterns for patients who received third-line or later (3L+) therapy using a multiple index date qualification methodology to enable a comparison to clinical trials. Methods: This observational, retrospective study identified eligible patients in the COTA (now Verana Health) electronic health record-based, DLBCL dataset. Patients were assessed for eligibility at the initiation of each 3L+ LOT. The results were summarized overall and by qualification methodology, and the Kaplan-Meier method was used to evaluate real-world overall survival (rwOS). Results: Among 476 unique patients, 716 index-LOTs were identified, and 3L+ index therapies were variable. The Eastern Cooperative Oncology Group (ECOG) score was 0-2 for 57% of qualifying-LOTs and missing/unknown (M/U) for 43%. The median rwOS among all-qualifying, first-qualifying, and last-qualifying index-LOTs was 8.0 (95% CI: 6.9, 10.6), 11.4 (95% CI: 9.7, 13.6), and 6.3 months (95% CI: 5.3, 8.0), respectively. Patients with M/U ECOG did not experience worse outcomes compared to those with ECOG 0-2. Conclusions: The outcomes in our study are similar to those from comparator arms of contemporary clinical trials, demonstrating a continued unmet need for effective, SOC therapy for patients with 3L+ DLBCL. Additionally, the variable outcomes based on qualifying index-LOTs underscores the criticality of appropriate patient identification and comparison for clinical trials.",
  "abstract_shown": true,
  "affiliations": [
    "Pfizer, Ltd., Walton Oaks, Tadworth KT20 7NS, UK.",
    "Pfizer, Inc., Collegeville, PA 19426, USA.",
    "Pfizer, Inc., Bothell, WA 98021, USA.",
    "Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Michael Wallington",
      "orcid": "0009-0001-0816-040X"
    },
    {
      "affs": [
        1
      ],
      "name": "Yong Chen"
    },
    {
      "affs": [
        2
      ],
      "name": "Fei Jie"
    },
    {
      "affs": [
        2
      ],
      "name": "Monica Patterson"
    },
    {
      "affs": [
        2
      ],
      "name": "Karen Repetny"
    },
    {
      "affs": [
        2
      ],
      "name": "Michelle Fanale"
    },
    {
      "affs": [
        0
      ],
      "name": "Simon Purcell"
    },
    {
      "affs": [
        3
      ],
      "name": "Jacob Ambrose"
    },
    {
      "affs": [
        3
      ],
      "name": "Christina M Zettler",
      "orcid": "0000-0002-7516-593X"
    },
    {
      "affs": [
        3
      ],
      "name": "Andrew J Belli"
    },
    {
      "affs": [
        3
      ],
      "name": "Laura L Fernandes"
    },
    {
      "affs": [
        3
      ],
      "name": "Ching-Kun Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/etp9kjn27qyt9.bib",
  "cited_by": 0,
  "doi": "10.3390/jcm15197596",
  "fulltext_url": "https://europepmc.org/articles/PMC13665813",
  "id": "etp9kjn27qyt9",
  "issns": [
    "2077-0383"
  ],
  "landing_url": "https://europepmc.org/article/MED/42882057",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2734|Lymphoma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7214897258",
  "pdf_url": "https://europepmc.org/articles/PMC13665813?pdf=render",
  "pmcid": "PMC13665813",
  "pmid": "42882057",
  "published": "2026-09-30",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/etp9kjn27qyt9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:16Z",
      "native_id": "MED:42882057",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42882057"
    },
    {
      "first_seen": "2026-10-30T12:20:00Z",
      "native_id": "10.3390/jcm15197596",
      "source": "crossref",
      "url": "https://www.mdpi.com/2077-0383/15/19/7596"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2734|Lymphoma Diagnosis and Treatment",
      "subfield": "general"
    }
  ],
  "title": "Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.",
  "title_text": "Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:00Z",
  "url": "https://research.draconitic.com/paper/etp9kjn27qyt9",
  "venue": "Journal of clinical medicine",
  "versions": []
}